Nektar Therapeutics (NKTR) Long-Term Investments (2011 - 2026)

Nektar Therapeutics' Long-Term Investments history runs 14 years deep, the most recent figure standing at $163.0 million for Q1 2026.

• In Q1 2026, Long-Term Investments rose 2001.24% year-over-year to $163.0 million; the TTM figure through Mar 2026 stood at $163.0 million (up 2001.24% YoY), while the FY2024 annual figure was $12.2 million, down 52.69% from the prior year.
• Long-Term Investments for Q1 2026 stood at $163.0 million, up from $5.4 million in the prior quarter.
• The five-year high for Long-Term Investments was $163.0 million in Q1 2026, with the low at $4.5 million in Q3 2024.
• The 5-year median for Long-Term Investments is $15.8 million (2024), against an average of $32.1 million.
• The sharpest annual moves came in 2022 and 2026: Long-Term Investments sank 84.45% in 2022, then soared 2001.24% in 2026.
• Nektar Therapeutics' Long-Term Investments stood at $8.9 million in 2022, then jumped by 189.26% to $25.8 million in 2023, then plunged by 52.69% to $12.2 million in 2024, then tumbled by 56.04% to $5.4 million in 2025, then surged by 2934.69% to $163.0 million in 2026.
• Business Quant data shows NKTR's Long-Term Investments at $163.0 million in Q1 2026, $5.4 million in Q2 2025, and $7.8 million in Q1 2025.